Project Grant R21DA057513
Award Date 8/1/24
Completion Date 7/31/26
Dollars Obligated $233K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $334,343 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Syncanica Bio, Inc. on June 15, 2025. The goal of this award is to develop and market a synthetic analog of 8,9-dihydrocannabidiol (H2CBD) as a therapeutic agent for the treatment of substance use disorder, a significant public health crisis. This builds upon Syncanica Bio's existing research on the...
- This Project Grant award of $144,950.00 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the expression, function, and immunomodulatory potential of endocannabinoid receptors, including TRPV2 and PPAR-A, as well as cannabidiol (CBD), in microglia in the context of HIV. The research goal is to investigate how the endocannabinoid system can modulate the HIV-induced inflammatory response in microglia, which is a key driver of...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $1,320,580 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in Missouri. The grant will fund preclinical studies to evaluate the analgesic potential of a novel, peripherally-restricted cannabinoid type 1 receptor (CB1R) agonist called VIP36. The key objectives are to assess VIP36's efficacy in mouse models of post-traumatic headache,...
- This Project Grant award, totaling $268,470.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The project will study the impacts of recent state-level laws legalizing medical cannabidiol (CBD) on substance use, including CBD use, opioid use, and alcohol use, as well as associated overdose rates. The research team, led by the RAND Corporation, will also collect and publish data on CBD dispensary locations and...
- The U.S. National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $686,692 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Medical University of South Carolina. The grant will fund an 8-week clinical trial to assess the prospective changes in patient-reported and objective functioning following reduction of cannabis use among adults with cannabis use disorder. The trial will evaluate the benefits of cannabis harm...
- The University of Texas Health Science Center at San Antonio (UTHSCSA) received a $154,880 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) on May 1, 2025. The purpose of this award is to evaluate cannabidiol (CBD) as a potential adjuvant treatment to buprenorphine for improving outcomes for patients with opioid use disorder (OUD). The key objectives of the study are to: 1) Examine how chronically administered...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will provide $350,000 to Creighton University to investigate the effects of environmental enrichment on the abuse liability of minor cannabinoids such as delta-8-THC and CBD. The research aims to determine if adolescent exposure to high- or low-novelty environments can alter sensitivity to these cannabis compounds using animal models....
- This federal Project Grant award of $385,638 was provided by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the grant is to conduct research on the neurobehavioral consequences of chronic exposure to synthetic cannabinoids, also known as "synthetic marijuana", across different stages of lifespan development and between sexes. The research aims to elucidate the...
- This $616,372 federal Project Grant was awarded on July 15, 2025 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to identify neuronal, glial, and neural stem/progenitor cell transposable element (TE) transcriptional and epigenetic gene regulatory states involved in SIV, antiretroviral therapy, and cannabinoid exposure in a non-human primate model. Additionally, the research aims to identify TE expression...
- This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), totaling $1,742,971 and commencing on April 15, 2025, aims to investigate the role of cannabinoids in modulating cocaine-induced inflammasome activation and epigenetic regulation in the intestine and brain during HIV/SIV infection. The primary objectives are to: 1) examine the impact of cocaine and HIV/SIV on inflammasome activation and its...